Bruce spent 12 years at Genentech in a variety of leadership roles in drug development. As a Life Cycle Leader (LCL) he led multi-disciplinary teams to develop and optimize the long-term value of drug therapies in the auto-immune area. This included a new indication for Xolair in Chronic Urticaria.
Bruce also led the formation of two new functional groups within drug development: Real World Data Science focused on real world studies and outcomes and also Product Development Innovation focused on more effective clinical trials and development.
Bruce consistently challenges the status quo in ways that are organizationally, economically, and operationally realistic and coherent – in service of developing more effective and personalize therapies. He is passionate about leading strategic efforts to optimize the design and operational capabilities of our drug development model.
Prior to joining Genentech, Bruce was a strategy consultant with McKinsey & Company, and practiced primary care medicine as a Medical Officer with the US Navy and as a preventive medicine physician with the State of California Department of Public Health.
Bruce earned a BS in Economics from The University of Pennsylvania, an MD from NYU and an MPH from UC Berkeley. He lives in the East Bay with his wife, son and daughter.